Loading clinical trials...

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.

NCT00159770•Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

View on ClinicalTrials.gov

Summary

Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV).
•Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator

Exclusion Criteria

•A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients

Locations (43)

Pfizer Investigational Site

Aalborg, Denmark

Pfizer Investigational Site

Arhus C, Denmark

Pfizer Investigational Site

Augustenborg, Denmark

Pfizer Investigational Site

Ballerup Municipality, Denmark

Pfizer Investigational Site

Brovst, Denmark

Pfizer Investigational Site

Copenhagen, Denmark

Pfizer Investigational Site

Dianalund, Denmark

Pfizer Investigational Site

Esbjerg, Denmark

Pfizer Investigational Site

Esbjerg N, Denmark

Pfizer Investigational Site

Glostrup Municipality, Denmark

Key Dates

Start Date

November 1, 2001

Completion Date

September 1, 2004

Last Updated

February 21, 2021

Enrollment

290

Estimated participants

Conditions

SchizophreniaSchizoaffective DisorderPsychotic Disorders

Interventions

ziprasidone versus olanzapine , risperidone or quetiapine

DRUG

Panss , CGI-C, UKU-SERS-Pa

BEHAVIORAL

Blood tests

PROCEDURE

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITINGNA

Racial Disparities in the Expression of Paranoia

NCT07460453

ParanoiaPsychotic Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 21, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Racial Disparities in the Expression of Paranoia

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Develop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques